Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin

被引:9
|
作者
Yang, Emily Y. [1 ]
Howard, Grant R. [2 ]
Brock, Amy [2 ,3 ,4 ]
Yankeelov, Thomas E. [1 ,2 ,3 ,5 ,6 ,7 ]
Lorenzo, Guillermo [1 ,8 ]
机构
[1] Univ Texas Austin, Oden Inst Computat Engn & Sci, Austin, TX 78712 USA
[2] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA
[3] Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78712 USA
[4] Univ Texas Austin, Interdisciplinary Life Sci Program, Austin, TX 78712 USA
[5] Univ Texas Austin, Dept Diagnost Med, Austin, TX 78712 USA
[6] Univ Texas Austin, Dept Oncol, Austin, TX 78712 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA
[8] Univ Pavia, Dept Civil Engn & Architecture, Pavia, Italy
基金
美国国家卫生研究院;
关键词
mathematical oncology; mathematical modeling; population dynamics; chemotherapy; drug resistance; breast cancer; time-resolved microscopy; DRUG-RESISTANCE; TUMOR HETEROGENEITY; DOSE-DENSE; NEOADJUVANT THERAPY; RANDOMIZED-TRIAL; LOGISTIC MODEL; CHEMOTHERAPY; MECHANISMS; SCHEDULE; SURVIVAL;
D O I
10.3389/fmolb.2022.972146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of chemoresistance remains a significant cause of treatment failure in breast cancer. We posit that a mathematical understanding of chemoresistance could assist in developing successful treatment strategies. Towards that end, we have developed a model that describes the cytotoxic effects of the standard chemotherapeutic drug doxorubicin on the MCF-7 breast cancer cell line. We assume that treatment with doxorubicin induces a compartmentalization of the breast cancer cell population into surviving cells, which continue proliferating after treatment, and irreversibly damaged cells, which gradually transition from proliferating to treatment-induced death. The model is fit to experimental data including variations in drug concentration, inter-treatment interval, and number of doses. Our model recapitulates tumor cell dynamics in all these scenarios (as quantified by the concordance correlation coefficient, CCC > 0.95). In particular, superior tumor control is observed with higher doxorubicin concentrations, shorter inter-treatment intervals, and a higher number of doses (p < 0.05). Longer inter-treatment intervals require adapting the model parameterization after each doxorubicin dose, suggesting the promotion of chemoresistance. Additionally, we propose promising empirical formulas to describe the variation of model parameters as functions of doxorubicin concentration (CCC > 0.78). Thus, we conclude that our mathematical model could deepen our understanding of the cytotoxic effects of doxorubicin and could be used to explore practical drug regimens achieving optimal tumor control.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] A mathematical model for predicting the spatiotemporal response of breast cancer cells treated with doxorubicin
    Miniere, Hugo J. M.
    Lima, Ernesto A. B. F.
    Lorenzo, Guillermo
    Hormuth, David A.
    Ty, Sophia
    Brock, Amy
    Yankeelov, Thomas E.
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [2] A Mathematical Model of Breast Cancer Treatment with CMF and Doxorubicin
    Rachel Roe-Dale
    David Isaacson
    Michael Kupferschmid
    Bulletin of Mathematical Biology, 2011, 73 : 585 - 608
  • [3] A Mathematical Model of Breast Cancer Treatment with CMF and Doxorubicin
    Roe-Dale, Rachel
    Isaacson, David
    Kupferschmid, Michael
    BULLETIN OF MATHEMATICAL BIOLOGY, 2011, 73 (03) : 585 - 608
  • [4] The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells
    Mentoor, Ilze
    Engelbrecht, Anna-Mart
    van de Vyver, Mari
    van Jaarsveld, Paul J.
    Nell, Theo
    ADIPOCYTE, 2021, 10 (01) : 505 - 523
  • [5] Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models
    Adachi, Yayoi
    Yoshimura, Mayumi
    Nishida, Keiko
    Usuki, Hisanobu
    Shibata, Keiko
    Hattori, Masaya
    Kondo, Naoto
    Yatabe, Yasushi
    Iwata, Hiroji
    Kikumori, Toyone
    Kodera, Yasuhiro
    Nakanishi, Hayao
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 439 - 450
  • [6] The paracrine effects of fibroblasts on Doxorubicin-treated breast cancer cells
    Fourie, Carla
    Davis, Tanja
    Kriel, Jurgen
    Engelbrecht, Anna-Mart
    EXPERIMENTAL CELL RESEARCH, 2019, 381 (02) : 280 - 287
  • [7] Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin
    Kim, Tae Hyung
    Shin, Yu Jin
    Won, A. Jin
    Lee, Byung Mu
    Choi, Wahn Soo
    Jung, Jee H.
    Chung, Hae Young
    Kim, Hyung Sik
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2014, 1840 (01): : 615 - 625
  • [8] Does insulin make breast cancer cells resistant to doxorubicin toxicity?
    Lykhova, Oleksandra
    Zavelevich, Michael
    Philchenkov, Alex
    Vidasov, Nazar
    Kozak, Tamara
    Lozovska, Yulia
    Andrusyshyna, Iryna
    Bishayee, Anupam
    Borikun, Tetiana
    Lukianova, Natalia
    Chekhun, Vasyl
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (11) : 3111 - 3122
  • [9] A Synergistic Combination of Niclosamide and Doxorubicin as an Efficacious Therapy for All Clinical Subtypes of Breast Cancer
    Lohiya, Garima
    Katti, Dhirendra S.
    CANCERS, 2021, 13 (13)
  • [10] Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin
    Abu Ajaj, Khalid
    Graeser, Ralph
    Kratz, Felix
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 117 - 129